- In April 2025, AstraZeneca reported positive Phase III trial outcomes in South Africa for a novel combination therapy aimed at improving treatment responses for patients with advanced non-small cell lung cancer in the region. This initiative highlights their commitment to addressing specific local healthcare needs
- In March 2025, NeoImmuneTech introduced an enhanced formulation of their immunotherapy candidate, NT-I7, designed to work more effectively in combination with checkpoint inhibitors for patients with relapsed small cell lung cancer, offering a potential new option for this challenging disease
- In March 2025, Novartis presented real-world evidence from their partnership with the Bengaluru Cancer Centre, showcasing the impact of their targeted therapies and data analytics in delivering more personalized and improved treatment results for lung cancer patients in a real-world setting
- In February 2025, Genentech (Roche) announced a strategic collaboration with the Chesapeake Oncology Network, focusing on creating a more efficient pathway for oncologists to access crucial biomarker testing and the most appropriate targeted therapies for their lung cancer patients
- In January 2025, Bristol Myers Squibb presented updated long-term survival data from a significant study evaluating their combination immunotherapy regimen as a first-line treatment for non-small cell lung cancer, demonstrating the potential for durable benefits in this patient population
